Please assess the completion status of the following clinical trial:

Trial Title: Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who do have continuous contact with ill person (staff members, dormitory, family members), laboratory confirmed viral origin, during influenza/other acute viral respiratory disease season~* First exposure with the ill person who is present with symptoms of flu or acute respiratory viral infection (fever, intoxication, catarrhal symptoms) ≤ 48 hours~* Signed Informed Contest to participate in the study~* Contraception throughout the study~Exclusion Criteria:~* Interferone or interferone inducers intake, or substances with action on immune system intake less then 3 months before inclusion~* Anti-virals intake, other then investigational drug, throughout the study~* Vaccination for Influenza less than 1 year before inclusion~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ingavirin (Type: EXPERIMENTAL): Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) capsules, 90 mg once daily for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral capsule, once daily for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).